Pcn111 Comparison of Adverse Event Costs of Nivolumab+ipilimumab Versus Sunitinib for Previously Untreated Intermediate-/Poor-Risk Advanced Renal Cell Carcinoma in Switzerland

Oniangue-Ndza, C.; Gooden, K.M.; May, J.; Malcolm, Bill; Du, E.X.; Liu, Yin; Betts, Keith A.

doi:10.1016/j.jval.2019.09.308

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maculopapular rash is the most frequently reported cutaneous irAE (immune-related adverse event) of PD-1/PD-L1 and CTLA-4 inhibitors [ 2 ]. It is most commonly seen with CTLA-4 inhibitors or under dual anti-PD1/PD-L1 and anti-CTLA therapy [ 18 , 19 , 20 ]. Although its severity can vary, grade ≥3 skin rashes, which are defined by the involvement of more than 30% of BSA (body surface area), are not frequent ( Table 1 ) [ 2 , 5 ].…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Plachouri

Florou

Georgiou

et al. 2023

Cancers

View full text Add to dashboard Cite

The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Plachouri

Florou

Georgiou

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Aldin

Besiroglu

Adams

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil

Duarte

Veiga

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background A full understanding of the economic burden associated with treatment-related adverse events (AEs) can aid estimates of the incremental costs associated with incorporating new technologies and support cost-effective economic modeling in Brazil. In this context, the main objective of this work was to evaluate in a real-life database: (i) the direct medical cost of monitoring the occurrence of AEs (CMO); (ii) the direct medical cost of managing an identified AE (CMN); and (iii) the total direct medical cost of monitoring and managing AEs (TMC), in quarterly periods from 0 to 24 months of the monitoring of cancer patients who used a PD-1 inhibitor from the perspective of the supplementary health system in Brazil. Methods This study was conducted from the supplementary health system (SSS) perspective and followed the methodological guidelines related to cost-of-illness studies. A bottom-up (person-based) approach was used to assess the use of health resources to monitor and manage AEs during the use of PD-1 inhibitors, which made it possible to capture differences in the mean frequency of the use of health services with stratification results for different subgroups. As the Brazilian SSS is complex, asymmetric, and fragmented, this study used information from different sources. The methodology was divided into three parts: (i) Data Source: clinical management of AEs; (ii) Microcosting: management of the economic burden of AEs; (iii) Statistical analysis: stratification of results for different subgroups. Results Analysis of the economic burden of toxicity showed higher CMO costs than CMN in all the periods analyzed. In general, for every BRL 100 on average invested in the TMC of AEs, BRL 95 are used to monitor the occurrence of the AE and only BRL 5 to manage an identified AE. This work also showed that the sociodemographic characteristics of patients, the journey of oncological treatment, and the toxicity profile affect the economic burden related to AE. Conclusion This study provided real-world evidence of the economic burden of AEs associated with the use of PD-1 inhibitors in Brazil. This work also made methodological contributions by evaluating the economic burden of AE of PD-1 inhibitors considering the kinetics of toxicity occurrence and categorizing the costs in terms of CMO, CMN and TMC.

show abstract

Pcn111 Comparison of Adverse Event Costs of Nivolumab+ipilimumab Versus Sunitinib for Previously Untreated Intermediate-/Poor-Risk Advanced Renal Cell Carcinoma in Switzerland

Cited by 3 publications

References 0 publications

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil

Contact Info

Product

Resources

About